Back to today’s briefing

Story perspectives

Kennedy Jr. Eyes HHS Role, Targets Drug Pricing Reform

1/23/2025

40 6

Left

Kennedy Targets HHS

Robert F. Kennedy Jr. could take the helm at HHS, shaking up drug price negotiations with his critical stance on the pharmaceutical industry. This comes as Trump’s administration grapples with the pressure to maintain Medicare's framework, which seeks to slash costs for 15 essential medications, including the sought-after weight-loss drug Ozempic.

Center

Trump Reverses Healthcare

President Donald Trump has overturned key health care executive orders from the Biden administration, including one designed to reduce prescription drug costs for Medicare recipients, sparking concerns about the future of drug pricing. In a contrasting move, Medicare is set to negotiate prices for 15 medications, such as the widely-used weight-loss drugs Ozempic and Wegovy, with new rates rolling out in 2027.

History

Historical Context

Robert F. Kennedy Jr.'s potential leadership at HHS echoes historical tensions between government and the pharmaceutical industry. The 1962 Kefauver-Harris Amendment strengthened FDA oversight after thalidomide's tragedy, emphasizing drug safety. Recent moves to negotiate Medicare drug prices reflect ongoing debates about access and affordability, reminiscent of past reforms aimed at curbing rising healthcare costs and ensuring public safety.

1 of 3

Kennedy Targets HHS

Robert F. Kennedy Jr. could take the helm at HHS, shaking up drug price negotiations with his critical stance on the pharmaceutical industry. This comes as Trump’s administration grapples with the pressure to maintain Medicare's framework, which seeks to slash costs for 15 essential medications, including the sought-after weight-loss drug Ozempic.

1 / 3